J.Jpn. Surg. Soc.
ISSN 1880-1129

[Abstract] [Full Text PDF] （in Japanese / 1805KB） [Members Only And Two Factor Auth.]

J.Jpn. Surg. Soc.. 103(6): 492-494, 2002

Feature topic

THYROID CARCINOMA:GENETICS, DIAGNOSIS, CLINICAL FEATURES, AND SURGICAL TREATMENT

1) Department of Surgery, Teikyo University School of Medicine, Tokyo, Japan
2) Department of Pathology, Keio University School of Medicine, Tokyo, Japan

Hiroshi Takami1), Yoshifumi Ikeda1), Gengo Tajima1), Shigenao Kan1), Kaori Kameyama2)

The genes implicated in thyroid carcinoma can be categorized as oncogenes or tumor-suppressor genes. The RET oncogene has well-established roles in the development of both medullary and papillary thyroid carcinoma(PTC). Genetic testing for the germline RET mutation is commonly performed, and prophylactic thyroidectomy is carried out at an early stage. The demonstration of a RET rearrangement in a PTC patient may be prognostic factor. TSH-R and Gsα are associated with the development of toxic thyroid adenoma(AFTN). The ras oncogene is implicated in the early stages of development of several tumor types. In conclusion, germline screening for RET mutations is now commonly undertaken in patients with medullary thyroid carcinoma.

<< To previous page

To read the PDF file you will need Adobe Reader installed on your computer.